Eton Pharmaceuticals

OverviewSuggest Edit

Eton Pharmaceuticals, a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products. It primarily focuses on liquid products, including injectable, oral liquid, and ophthalmic products. The company develops EM-100, an ophthalmic product for the treatment of allergic conjunctivitis; ET-202 and ET-203, which are injectable product candidates for use in the hospital setting; ET-103, an oral liquid product candidate for hypothyroidism; ET-101, ET-102, and ET-104, which are oral liquid product candidates for neurological indications; and CT-100, a synthetic corticotropin therapeutic candidate for rheumatoid arthritis.

TypePublic
Founded2017
HQPalatine, IL, US
Websiteetonpharma.com

Latest Updates

Employees (est.) (Jun 2019)15
Share Price (Feb 2021)$8.2 (-4%)
Cybersecurity ratingAMore

Key People/Management at Eton Pharmaceuticals

Wilson Troutman

Wilson Troutman

Chief Financial Officer
Sean Brynjelsen

Sean Brynjelsen

Chief Executive Officer & Director
Norbert Riedel

Norbert Riedel

Chairman of the Board
Scott Grossenbach

Scott Grossenbach

Vice President, Sales & Marketing
Bharathi Devarakonda

Bharathi Devarakonda

SVP, Regulatory Affairs & Product Development
David Krempa

David Krempa

Vice President, Business Development
Show more

Eton Pharmaceuticals Office Locations

Eton Pharmaceuticals has an office in Palatine
Palatine, IL, US (HQ)
21925 W Field Pkwy #235
Show all (1)

Eton Pharmaceuticals Financials and Metrics

Eton Pharmaceuticals Revenue

USD

Net income (FY, 2018)

(12.7m)

Market capitalization (25-Feb-2021)

199.5m

Closing stock price (25-Feb-2021)

8.2

Cash (31-Dec-2018)

26.7m
Eton Pharmaceuticals's current market capitalization is $199.5 m.
USDFY, 2017FY, 2018

General and administrative expense

3.2m4.7m

R&D expense

3.9m5.6m

Operating expense total

7.2m10.3m

Net Income

(7.2m)(12.7m)
USDFY, 2017FY, 2018

Cash

13.2m26.7m

Prepaid Expenses

136.0k767.0k

Current Assets

13.3m27.5m

Total Assets

13.4m28.3m
USDFY, 2017FY, 2018

Net Income

(7.2m)(12.7m)

Depreciation and Amortization

13.0k63.0k

Accounts Payable

539.0k413.0k

Cash From Operating Activities

(4.7m)(8.1m)
USDFY, 2017

Financial Leverage

-2 x
Show all financial metrics

Eton Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Eton Pharmaceuticals Online and Social Media Presence

Embed Graph

Eton Pharmaceuticals News and Updates

Eton Pharmaceuticals to Participate in 10th Annual SVB Leerink Global Healthcare Conference

DEER PARK, Ill., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that company management will be participating in the 10th An…

Eton Pharmaceuticals Announces Sale of Neurology Portfolio

DEER PARK, Ill., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that it has sold its neurology portfolio to Azurity Pharmace…

Eton Pharmaceuticals Announces Acquisition of Canadian Rights for ALKINDI® SPRINKLE

DEER PARK, Ill., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that it has acquired Canadian rights to ALKINDI® SPRINKLE fr…

Eton Pharmaceuticals Announces Acceptance for Filing of New Drug Application for Topiramate Oral Solution

Application Assigned a PDUFA Date of August 6, 2021 Application Assigned a PDUFA Date of August 6, 2021

Eton Pharmaceuticals Announces Availability of Orphan Drug ALKINDI® SPRINKLE (hydrocortisone) in the United States

DEER PARK, Ill., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced the full availability of ALKINDI® SPRINKLE for sale and distr…

Eton Pharmaceuticals Announces Third Quarter 2020 Financial Results

DEER PARK, Ill., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today reported financial results for the third quarter ended September 30, 20…
Show more

Eton Pharmaceuticals Blogs

Eton Pharmaceuticals Announces Closing of Public Offering

Eton Pharmaceuticals Announces Closing of Public Offering Content Import Fri, 10/16/2020 - 16:06 Eton Pharmaceuticals Announces Closing of Public Offering October 16, 2020 at 4:05 PM EDT This release is a backfill from a News Wire General …

Eton Pharmaceuticals Prices Underwritten Public Offering of Common Stock

Eton Pharmaceuticals Prices Underwritten Public Offering of Common Stock Content Import Wed, 10/14/2020 - 08:31 Eton Pharmaceuticals Prices Underwritten Public Offering of Common Stock October 14, 2020 at 8:30 AM EDT This release is a backfill from a News Wire…

Eton Pharmaceuticals Announces Acceptance for Filing of New Drug Application for Orphan Drug Dehydrated Alcohol Injection

Eton Pharmaceuticals Announces Acceptance for Filing of New Drug Application for Orphan Drug Dehydrated Alcohol Injection Content Import Thu, 10/08/2020 - 08:02 Eton Pharmaceuticals Announces Acceptance for Filing of New Drug Application for Orphan Drug Dehydrated Alcohol Injection …

Eton Pharmaceuticals Submits New Drug Application to the FDA for Topiramate Oral Solution (ET-101)

Eton Pharmaceuticals Submits New Drug Application to the FDA for Topiramate Oral Solution (ET-101) Content Import Tue, 10/06/2020 - 16:06 Eton Pharmaceuticals Submits New Drug Application to the FDA for Topiramate Oral Solution (ET-101) October 6, 2020 at 4:05 PM EDT …

Eton Pharmaceuticals Reports Positive Study Results for ET-101 (Topiramate Oral Solution)

-Results Demonstrated Bioequivalence to the Currently Approved Oral Solid Formulation -Market for Topiramate in Oral Form is Greater than $800 million Annually DEER PARK, Ill. , March 17, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused

Eton Pharmaceuticals Announces Fourth Quarter and Full Year 2019 Financial Results

Eton Pharmaceuticals Announces Fourth Quarter and Full Year 2019 Financial Results Content Import Thu, 03/05/2020 - 16:02 Eton Pharmaceuticals Announces Fourth Quarter and Full Year 2019 Financial Results March 5, 2020 at 4:02 PM EST This release is a backfill…
Show more

Eton Pharmaceuticals Frequently Asked Questions

  • When was Eton Pharmaceuticals founded?

    Eton Pharmaceuticals was founded in 2017.

  • Who are Eton Pharmaceuticals key executives?

    Eton Pharmaceuticals's key executives are Wilson Troutman, Sean Brynjelsen and Norbert Riedel.

  • How many employees does Eton Pharmaceuticals have?

    Eton Pharmaceuticals has 15 employees.

  • Who are Eton Pharmaceuticals competitors?

    Competitors of Eton Pharmaceuticals include MyoKardia, Reata Pharmaceuticals and Biogen.

  • Where is Eton Pharmaceuticals headquarters?

    Eton Pharmaceuticals headquarters is located at 21925 W Field Pkwy #235, Palatine.

  • Where are Eton Pharmaceuticals offices?

    Eton Pharmaceuticals has an office in Palatine.

  • How many offices does Eton Pharmaceuticals have?

    Eton Pharmaceuticals has 1 office.